CYDY News and Press, CytoDyn Inc From 03/30/22

CytoDyn made changes to the CEO position and the company's board of directors. The company appears to have secured finances to keep the lights on for the time being. The company has gone into complete silence, which is a stark contrast to the company's previous practices. Investors ar...

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Boar...

About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms. While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the ...

Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million people globally. According to the World Health Organization (WHO), more than 100 million people suffer from long CO...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CytoDyn Inc. (OTC: CYDY). Beginning in early 2020, the Company began pivoting its e...

Initiates Search for New CEO With Requisite Pharmaceutical Industry Experience Antonio Migliarese Appointed Interim President Today the Board of Directors (“the Board”) of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company ...

3 Popular Penny Stocks to Watch in January 2022 As another trading day comes to an end for penny stocks and blue chips, we’re witnessing extremely high volatility in the stock market. When trading began today, it looked as though the market was headed for a bullish day. Howev...

Company Will Provide Update at Future Date CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced ...

VANCOUVER, Washington, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D.,...

Regnum Signs Assignment and Assumption Agreement with CytoDyn and SevenScore Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, SevenSco...